INVA Stock Summary and Trading Ideas (Innoviva | NASDAQ:INVA)

Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.

Innoviva trades on the NASDAQ stock market under the symbol INVA.

As of April 17, 2026, INVA stock price climbed to $24.24 with 609,437 million shares trading.

INVA has a beta of 0.05, meaning it tends to be less sensitive to market movements. INVA has a correlation of 0.00 to the broad based SPY ETF.

INVA has a market cap of $1.80 billion. This is considered a Small Cap stock.

Last quarter Innoviva reported $115 million in Revenue and $1.94 earnings per share. This beat revenue expectation by $12 million and exceeded earnings estimates by $1.55.

In the last 3 years, INVA traded as high as $25.15 and as low as $11.24.

The top ETF exchange traded funds that INVA belongs to (by Net Assets): IJR, VTI, IWM, VB, AVUV.

INVA has underperformed the market in the last year with a price return of +32.7% while the SPY ETF gained +36.3%. However, in the short term, INVA had mixed performance relative to the market. It has outperformed in the last 3 months, returning +24.7% vs +2.9% return in SPY. But in the last 2 weeks, INVA shares have been beat by the market, returning +5.4% compared to an SPY return of +8.3%.

INVA support price is $23.20 and resistance is $24.00 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INVA shares will trade within this expected range on the day.